GlassScriptPhysician profile
Deborah M Horvitz
NPI 1427457142
$10,198.12
in general payments reported to CMS, 2019-2025
23 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,438 · 2022: $2,255 · 2023: $2,048 · 2024: $2,331 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,495 · Education: $9.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,494.78 |
| Education | $9.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,162.65 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,182.57 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,078.31 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $886.89 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $828.27 | 2022-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $780.35 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $686.46 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $674.20 | 2021-2025 | Rexulti |
| Corium, LLC | $335.38 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $328.74 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $284.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.03 | 2021-2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $187.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $130.04 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $87.72 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $61.21 | 2021 | |
| Sage Therapeutics, LLC | $60.95 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $45.59 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $42.30 | 2021-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $35.30 | 2023-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $30.11 | 2023 | Quviviq |
| Almatica Pharma LLC | $19.71 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.37 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Horvitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.